Sirnaomics Receives FDA Clearance to Initiate Phase 2 Study of STP705 for the Treatment of Non-Melanoma Skin Cancer
GAITHERSBURG, MD, USA, December 20, 2018 /EINPresswire.com/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, announced today that the U.S. Food and Drug …